Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7449124 | 0.98 | MAPT (0.44) | GSRRNPEPALDH1A1MAPTCPB2 | |
| SCHEMBL9830216 | 0.95 | MAPT (0.44) | GSRRNPEPMAPTCPB2GNAI3 | |
| SCHEMBL2123199 | 0.95 | ALDH1A1 (0.44) | GSRALDH1A1MAPTCPB2ATM | |
| SCHEMBL9184074 | 0.93 | MAPT (0.47) | MAPTCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL9362410 | 0.93 | MAPT (0.47) | MAPTCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL9832203 | 0.90 | NAAA (0.43) | ALDH1A1MAPTCPB2HCAR2GPR84 | |
| SCHEMBL9830707 | 0.90 | CPB2 (0.45) | GSRRNPEPMAPTCPB2GNAI3 | |
| SCHEMBL5983037 | 0.89 | ALDH1A1 (0.45) | ALDH1A1MAPTATMHCAR2 | |
| SCHEMBL28070253 | 0.87 | MAPT (0.55) | ALDH1A1MAPTATMHCAR2GPR84 | |
| SCHEMBL7633731 | 0.87 | ALDH1A1 (0.50) | ALDH1A1MAPTATMHCAR2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0773950-A4 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0804456-A4 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 1999-05-19 | — | — | EP | disclosed |
| EP-0804456-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0773950-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996011205-A9 | PEPTIDE NUCLEIC ACID CONJUGATES | — | 1996-05-30 | — | — | WO | disclosed |
| WO-1996011205-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996002558-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |